← Leaderboards
Allen R. Comer
Stratatech Corporation
$10,946,387
Attributed
$13,077,282
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2006–13$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$13,077,282 · 5
By mechanism
R44$13,077,282 · 5
Top collaborators
- Mary A. Lokuta3 shared
Most similar at Stratatech Corporation
Same institution · by research overlap
- Mary A. Lokuta$3,821,515
- John M Centanni$2,752,711
- Allen R Comer$2,615,363
- Barbara Lynn Allen-Hoffmann$2,350,666
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesChronicWoundSkinClinical TrialsKeratinocyteSkin TissueCellsPathogenProductionHealingHealedEngineeringDesignSmall Business Innovation Research GrantCell LineLifeInnovationBiologicalPropertyWound HealingManufacturing ProcessMarketingAnimal Model
Grant awards (20)
Clinical Trial of Antimicrobial Skin to treat Diabetic Ulcers$1,049,455
R44 · FY2013 · DK
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$978,425
R44 · FY2013 · AI · contact PI
Clinical Trial of Antimicrobial Skin to treat Diabetic Ulcers$1,931,207
R44 · FY2012 · DK
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$980,388
R44 · FY2012 · AI · contact PI
Development of a Cell-Derived Human Skin Substitute for Acute and Chronic Wounds$499,952
R44 · FY2012 · AR · contact PI
A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce$1,281,128
R44 · FY2011 · DK
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$1,000,000
R44 · FY2011 · AI · contact PI
Development of a Cell-Derived Human Skin Substitute for Acute and Chronic Wounds$499,868
R44 · FY2011 · AR · contact PI
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$500,000
R44 · FY2010 · AI · contact PI
Development of a Cell-Derived Human Skin Substitute for Acute and Chronic Wounds$499,841
R44 · FY2010 · AR · contact PI
Enhancing the Vascularization Properties of Skin Tissue$536,289
R44 · FY2009 · AG · contact PI
Enhancing the Vascularization Properties of Skin Tissue$99,916
R44 · FY2009 · AG · contact PI
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$872,419
R44 · FY2008 · DK · contact PI
Enhancing the Vascularization Properties of Skin Tissue$477,964
R44 · FY2008 · AG · contact PI
Closed, Aseptic Production Process for Engineered Living Human Skin Tissue$395,388
R44 · FY2008 · AG · contact PI
Enhancing the Vascularization Properties of Skin Tissue$608,811
R44 · FY2007 · AG · contact PI
Closed, Aseptic Production Process for Engineered Living Human Skin Tissue$412,035
R44 · FY2007 · AG · contact PI
Clinical Evaluation of StrataGraft Skin Tissue$123,254
R44 · FY2007 · AR · contact PI
Closed, Aseptic Production Process for Engineered Living Human Skin Tissue$196,099
R44 · FY2006 · AG · contact PI
Clinical Evaluation of StrataGraft Skin Tissue$134,843
R44 · FY2006 · AR · contact PI